相关实验视频

Updated: Jul 26, 2025

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

多发性骨髓瘤中的双特异单克隆抗体:来自ASH 2022的数据:播客

Ola Landgren¹, Omar Nadeem²

¹Sylvester Comprehensive Cancer Center, Miami, FL, USA. col15@miami.edu.

Advances in therapy

|June 16, 2023

概括

针对BCMA,GPRC5D和FcRH5的新型双特异性抗体 (BsAb) 对复发性/耐药性多发性骨髓瘤 (MM) 显示出有前途. 这些T细胞重定向疗法为重度预治疗的患者提供了改善的结果.

科学领域:

血液学血液学血液学
免疫治疗是一种免疫疗法.
在瘤学瘤学.

背景情况:

多发性骨髓瘤 (MM) 治疗已经被免疫疗法彻底改变,但治愈仍然难以捉摸.
严重预先治疗的MM患者面临着有限的生存期,突出显示出未满足的临床需求.
具有独特作用机制的新型疗法对于改善MM患者的治疗结果至关重要.

研究的目的:

总结新兴的T细胞重定向双特异性抗体 (BsAb) 对于复发性/耐火性多发性骨髓瘤 (MM).
为了突出在美国血液学会2022年会议上提出的临床数据.
将重点放在针对BCMA,GPRC5D和FcRH5.5的BsAb上

主要方法:

对MM中T细胞重定向BsAb的临床第一阶段和第二阶段研究的审查.
对Bs.Ab.在ASH 2022口头会议上提出的数据分析.
专注于特定的BsAb:talquetamab,elranatamab,teclistamab,forimtamig,和alnuctamab. 这三种药物是最重要的.

主要成果:

针对BCMA,GPRC5D和FcRH5的几个BsAb显示出显著的临床活性.
早期研究 (第一阶段和第二阶段) 报告了有希望的安全性和疗效数据.
这些药物正在为具有挑战性的复发性/耐药性MM群体开发.

结论:

重定向T细胞的BsAb代表了MM治疗的重大进展.
这些新药预计将成为未来MM治疗方案的组成部分.
持续的研究和开发对于优化MM的BsAb疗法至关重要.

关键词:

双特异性抗体双特异性抗体临床试验临床试验是指临床试验的临床试验.多发性骨髓瘤是一种多发性骨髓瘤.播客播客播客

更多相关视频

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

相关概念视频

Hybridoma Technology

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...